On April 4, 2024, the US Food and Drug Administration accepted a supplemental Biologics License Application (sBLA) to review bimekizumab-bkzx, an interleukin (IL)-17A and IL-17F inhibitor, […]

TOPLINE: A review of 22 articles found a higher incidence of “altered skin sensations” and alopecia in individuals receiving oral semaglutide than in those receiving placebo. […]

TOPLINE: When combined with low-dose corticosteroids, a Bruton tyrosine kinase (BTK) inhibitor rilzabrutinib did not result in complete remission (CR) in patients with newly diagnosed or […]

SAN DIEGO — Patients with mild hidradenitis suppurativa (HS) treated with ruxolitinib cream experienced a greater reduction in the abscess and inflammatory nodule (AN) count from […]

SAN DIEGO — When Jennifer Adams, MD, recently entered the search term “warts” on the ClinicalTrials.gov web site, nearly 240 results popped up. “There is a […]

San Diego — In two different phase 2b trial extensions, oral treatment with Janus kinase (JAK) inhibitors showed improved skin clearance, according to presentations at a […]

TOPLINE: Hypoplastic pitted amelogenesis imperfecta may affect patients with the rare genetic disorder Kindler epidermolysis bullosa (KEB). METHODOLOGY: KEB or Kindler syndrome, a genetic skin-blistering disease […]

TOPLINE: Despite a high frequency of atypical features, longitudinal melanonychia (LM) in children is associated with an exceedingly low rate of malignancy. METHODOLOGY: LM — a […]

The US Food and Drug Administration (FDA) warned consumers in a statement issued on March 26 to avoid certain unapproved over-the-counter topical analgesic products because of […]